Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Retifanlimab
Related studies linked through entity extraction aliases.
HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Retifanlimab and Ruxolitinib In Solid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
- Status
- RECRUITING
- Phase
- PHASE1
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
- Status
- AVAILABLE
- Phase
- N/A
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
- Status
- RECRUITING
- Phase
- PHASE2
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Status
- RECRUITING
- Phase
- PHASE1
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
- Status
- RECRUITING
- Phase
- PHASE2
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Status
- RECRUITING
- Phase
- PHASE3
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1